Xencor Inc (XNCR)
19.96
+0.73
(+3.80%)
USD |
NASDAQ |
Apr 26, 16:00
19.96
0.00 (0.00%)
After-Hours: 20:00
Xencor Research and Development Expense (Quarterly): 64.22M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 64.22M |
| September 30, 2023 | 64.94M |
| June 30, 2023 | 60.06M |
| March 31, 2023 | 64.38M |
| December 31, 2022 | 51.45M |
| September 30, 2022 | 53.27M |
| June 30, 2022 | 47.08M |
| March 31, 2022 | 47.76M |
| December 31, 2021 | 50.99M |
| September 30, 2021 | 50.61M |
| June 30, 2021 | 49.50M |
| March 31, 2021 | 41.41M |
| December 31, 2020 | 47.95M |
| September 30, 2020 | 44.45M |
| June 30, 2020 | 43.46M |
| March 31, 2020 | 33.94M |
| December 31, 2019 | 27.34M |
| September 30, 2019 | 29.77M |
| June 30, 2019 | 33.30M |
| March 31, 2019 | 28.18M |
| December 31, 2018 | 27.13M |
| September 30, 2018 | 20.95M |
| June 30, 2018 | 23.33M |
| Date | Value |
|---|---|
| March 31, 2018 | 26.09M |
| December 31, 2017 | 20.40M |
| September 30, 2017 | 19.41M |
| June 30, 2017 | 16.92M |
| March 31, 2017 | 15.05M |
| December 31, 2016 | 13.36M |
| September 30, 2016 | 14.07M |
| June 30, 2016 | 14.41M |
| March 31, 2016 | 10.04M |
| December 31, 2015 | 10.88M |
| September 30, 2015 | 10.58M |
| June 30, 2015 | 7.476M |
| March 31, 2015 | 5.205M |
| December 31, 2014 | 5.052M |
| September 30, 2014 | 4.953M |
| June 30, 2014 | 4.283M |
| March 31, 2014 | 4.228M |
| December 31, 2013 | 4.143M |
| September 30, 2013 | 4.163M |
| June 30, 2013 | 4.134M |
| March 31, 2013 | 4.56M |
| December 31, 2012 | 3.943M |
| September 30, 2012 | 3.046M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
27.34M
Minimum
Dec 2019
64.94M
Maximum
Sep 2023
47.68M
Average
47.95M
Median
Dec 2020
Research and Development Expense (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | 256.56M |
| Karyopharm Therapeutics Inc | 39.38M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |